Foresite Capital has added a new venture partner to its team. The executive leader, Dr. Molly He, is the former senior director at Illumina. Her appointment will help the healthcare growth equity firm to enhance its growth and profitability margins. Dr. He boasts of over 15 years of experience in the healthcare industry. She has spent most of those years in pharmaceutical and genomic research.
Speaking during the announcement of the new venture partner, Jim Tananbaum, praised the researcher as an experienced person in the field of next-generation sequencing. The chief executive officer of Foresite Capital added that Dr. He’s acceptance to work for the company is a testament to their commitment to providing the public with innovative solutions. The researcher has a proven record in transforming different companies, including Illumina. Jim also believes that her experience will be an invaluable resource at Foresite Capital. The company is focusing on expanding and diversifying its portfolio, which is made up of transformational companies.
At Illumina, Dr. He was in charge of scientific research. In this position, she was responsible for overseeing the company’s global research in protein reagent innovation and improvements. In addition, Dr. He worked for Pacific Biosciences as the head of protein sciences. At the company, she played a pivotal role in developing its single real-time sequencing chemistry. Moreover, the scientist has provided visionary leadership for various companies in the pharmaceutical industry.
Dr. He’s success in the healthcare industry is attributed to her sound educational background. The transformative leader holds a bachelor’s degree in biochemistry from the Nankai University. She has a doctorate degree in protein biophysics from the Los Angeles-based University of California. The researcher has written over 20 published scientific papers. Dr. Molly has also applied for over 20 patents focusing on next-generation sequencing and personalized medicine.
Jim Tananbaum is a San Francisco-based entrepreneur and executive leader. The business manager has been heavily involved in the founding of several companies, including Foresite Capital. The venture firm has over $1.1 billion in assets under its management. Jim is also the brain behind Theravance(THRX), Prospect Venture Partners, and GelTex. He is a proud alumnus of Harvard Medical School, Harvard Business School, Massachusetts Institute of Technology (MIT), and Yale University. Check out Medium to know more.
Visit his profile About.me